21:17 , Jun 20, 2019 |  BC Innovations  |  Emerging Company Profile

Casma: Tailoring autophagy targets to indications

Rather than focus on a single target, Casma is evaluating the entire autophagy pathway for a broad swath of diseases. According to Casma Therapeutics Inc. CEO Keith Dionne, inappropriate accumulation of autophagy substrates is shared...
21:44 , Jan 5, 2018 |  BC Week In Review  |  Financial News

resTORbio proposes $85M IPO

resTORbio Inc. (Boston, Mass.) proposed on Dec. 29, 2017, to raise $85 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Leerink Partners, Evercore ISI and Wedbush PacGrow. In November, the aging-related disease...
21:55 , Dec 1, 2017 |  BC Week In Review  |  Financial News

resTORbio raises $40M series B

resTORbio Inc. (Boston, Mass.) raised $40 million in an oversubscribed series B round led by OrbiMed Advisors with participation from Fidelity, Rock Springs Capital, Quan Capital and Nest Bio. The aging-related disease company has raised...
20:40 , Nov 30, 2017 |  BC Extra  |  Financial News

resTORbio raises $40M

resTORbio Inc. (Boston, Mass.) raised $40 million in an oversubscribed series B round led by OrbiMed Advisors with participation from Fidelity, Rock Springs Capital, Quan Capital and Nest Bio. The aging-related disease company has raised...
07:00 , Jul 21, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

REGULATORY MILESTONES Basilea Pharmaceutica AG (SIX:BSLN) was up CHF0.35 to CHF97.90 last week after submitting an MAA to EMA for isavuconazole to treat invasive aspergillosis and invasive mucormycosis (zygomycosis). Partner Astellas Pharma Inc. (Tokyo:4503) submitted...
00:46 , Jul 16, 2014 |  BC Extra  |  Financial News

RestorGenex raises $35.6 million

RestorGenex Corp. (OTCQB:RESX) raised $35.6 million through the sale of 8.9 million units at $4 in a private placement to institutional investors, including Ally Bridge Group, and accredited investors. Each unit comprises a share and...
07:00 , May 22, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) CREB-regulated transcription coactivator 1 (CRTC1; TORC1) Human and mouse studies suggest agonizing CRTC1 could help treat AD. In patients with intermediate and...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Paloma, RestorGenex, VasculoMedics deal

Stratus Media Group Inc. merged with Paloma and VasculoMedics and subsequently changed its name to RestorGenex. The new company will focus on dermatology, ocular diseases and women's health. The merger was approved by the boards...
07:00 , Jun 10, 2013 |  BioCentury  |  Emerging Company Profile

ONL Therapeutics: Eyeing Fas

ONL Therapeutics LLC is developing a peptide antagonist of Fas-mediated apoptosis that could become the first pharmacotherapy to prevent vision loss associated with non-exudative retinal detachment. The company expects its products would be used as...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Clinical News

Paloma preclinical data

In a mouse xenograft model of HRPC, Palomid 529 significantly reduced tumor volume vs. vehicle-treated controls at day 24 (p<0.05). Additionally, Palomid 529 plus cisplatin, Taxotere docetaxel or radiotherapy significantly reduced tumor volume compared to...